1042 related articles for article (PubMed ID: 33825837)
1. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):631-641. PubMed ID: 38776431
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
7. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
8. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma.
Cai C; Yunusa I; Tarhini A
JAMA Netw Open; 2021 Nov; 4(11):e2132262. PubMed ID: 34762112
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.
Gong H; Ong SC; Li F; Weng Z; Zhao K; Jiang Z
Cost Eff Resour Alloc; 2023 Mar; 21(1):20. PubMed ID: 37004046
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Li Y; Liang X; Li H; Chen X
Cancer; 2022 Nov; 128(22):3995-4003. PubMed ID: 36111952
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
Zhao M; Pan X; Yin Y; Hu H; Wei J; Bai Z; Tang W
Front Public Health; 2022; 10():869960. PubMed ID: 35493395
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Hou Y; Wu B
Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
[No Abstract] [Full Text] [Related]
17. Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
Qin S; Yi L; Li S; Tan C; Zeng X; Wang L; Peng Y; Wan X
Adv Ther; 2021 Jun; 38(6):3399-3408. PubMed ID: 34019245
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
[TBL] [Abstract][Full Text] [Related]
19. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Wang L; Peng Y; Qin S; Wan X; Zeng X; Li S; Liu Q; Tan C
PLoS One; 2023; 18(4):e0279786. PubMed ID: 37053300
[TBL] [Abstract][Full Text] [Related]
20. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Chiang CL; Chan SK; Lee SF; Choi HC
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]